Universal Beteiligungs und Servicegesellschaft mbH Buys New Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 94,011 shares of the company's stock, valued at approximately $3,235,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.16% of Harmony Biosciences at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC grew its holdings in Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company's stock valued at $3,074,000 after buying an additional 40,416 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in Harmony Biosciences by 9.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock valued at $600,000 after buying an additional 1,550 shares in the last quarter. KBC Group NV grew its holdings in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after buying an additional 819 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Harmony Biosciences by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,093 shares of the company's stock valued at $416,000 after buying an additional 1,162 shares in the last quarter. Finally, Yousif Capital Management LLC grew its holdings in Harmony Biosciences by 22.4% during the 4th quarter. Yousif Capital Management LLC now owns 14,325 shares of the company's stock valued at $493,000 after buying an additional 2,622 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Trading Up 1.6%

HRMY stock traded up $0.57 during midday trading on Friday, hitting $35.60. The company had a trading volume of 441,103 shares, compared to its average volume of 615,337. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The stock's 50 day moving average price is $31.77 and its 200 day moving average price is $34.05. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 0.47 and a beta of 0.87.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. As a group, equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HRMY has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Oppenheimer started coverage on Harmony Biosciences in a research report on Monday. They set an "outperform" rating and a $61.00 price target for the company. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price for the company. UBS Group dropped their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Finally, Needham & Company LLC restated a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Harmony Biosciences has a consensus rating of "Buy" and an average price target of $53.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.